To help hospitals and health systems meet demand during the current surge in respiratory illnesses for fever-reducing products to treat pediatric patients and adults unable to swallow solid oral dosage forms, the Food and Drug Administration Friday released guidance for outsourcing facilities compounding certain ibuprofen oral suspension products.

“Although FDA is monitoring the global pharmaceutical supply chain and working, within its authorities, with manufacturers of approved ibuprofen oral suspension products, to bolster supply, temporary flexibility is needed to help ensure that treatment options are available to hospitals and health systems during this period of increased demand,” the guidance states. 

Related News Articles

Headline
President Trump, late Sept. 25, announced that starting Oct. 1, the U.S. will impose a 100% tariff on any branded or patented pharmaceutical product, unless a…
Headline
The Department of Commerce Sept. 24 released a notice seeking public comment on an investigation it launched Sept. 2 on imports of personal protective…
Headline
The Food and Drug Administration has identified a Class I recall of certain Olympus ViziShot 2 FLEX Needles due to a possible patient safety issue caused by a…
Headline
The White House Sept. 5 issued an executive order modifying the scope of reciprocal tariffs announced in April to establish a framework of trade deals with…
Headline
A JAMA study published Aug. 20 found that nearly 63% of all U.S. drug production facilities from 2019 through 2024 were in counties where a weather disaster…
Headline
B. Braun Medical has voluntarily recalled two lots of Lactated Ringer’s Injection USP 1000 mL and 0.9% Sodium Chloride Injection USP 1000 mL IV fluids due to…